| Previous Close | 29.02 |
| Open | 29.19 |
| Bid | 26.50 x 800 |
| Ask | 31.10 x 800 |
| Day's Range | 28.58 - 30.90 |
| 52 Week Range | 24.26 - 34.70 |
| Volume | 153,301 |
| Avg. Volume | 370,920 |
| Market Cap | 906.061M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
SOUTH SAN FRANCISCO, Calif., May 27, 2020 -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address.
SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address.
Successful completion of $138.0 million initial public offering; cash and cash equivalents of $204.2 million as of April 30th expected to fund current operating plan into 2023.
SOUTH SAN FRANCISCO, Calif., April 28, 2020 -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address.
The preclinical data on ORIC’s CD73 program were presented in the “Advances in Cancer Drug Design and Discovery” session in an oral presentation titled “Orally Available Small Molecule CD73 Inhibitor Reverses Immunosuppression Through Blocking of Adenosine Production” (Abstract #1242, presentation 1037). Many cancers usurp the anti-inflammatory adenosine pathway to avoid detection by the immune system, thereby reducing the effectiveness of certain chemotherapy- and immunotherapy-based treatments.
SOUTH SAN FRANCISCO, Calif., April 23, 2020 -- ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), a clinical stage oncology company focused on developing treatments that address.